Illumina
Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
CEO photo:
Website: www.illumina.com
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founded: 1998
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina News
Avitia Launches With C$5M in Seed Financing to Advance Molecular Testing Platform
The platform will enable on-site molecular profiling of liquid biopsy samples for cancer patient monitoring and treatment response prediction.
Aetna Revises Fetal Aneuploidy Screening Policy to Include Natera, BillionToOne Tests
The policy considers cfDNA testing medically necessary in cases such as a risk of alloimmunization and where amniocentesis is declined or contraindicated.
Clinical customers helped Illumina place 91 NovaSeq X instruments in the fourth quarter. CFO Ankur Dhingra said many planned to use them for MRD testing.
Illumina to Incorporate Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay
GIS measures DNA repair defects via loss of heterozygosity, large-scale state transition, and telomere allele imbalance.
In Brief This Week: Abbott, Personalis, Aspira Women's Health, Thermo Fisher Scientific, Illumina, More
News items for the week of Nov. 4, 2024.